Literature DB >> 30054180

Movement disorders in cerebrotendinous xanthomatosis.

Bianca M L Stelten1, Bart P C van de Warrenburg2, Ron A Wevers3, Aad Verrips4.   

Abstract

Cerebrotendinous xanthomatosis (CTX) is an inborn error of cholesterol and bile acid metabolism, leading to neuropsychiatric and systemic manifestations. Movement disorders have rarely been reported in CTX, while a detailed appreciation of the full phenotypic spectrum is required in order to prevent underdiagnosis of this disease. This review focuses on the frequency of more unusual, non-ataxia and non-spasticity movement disorders reported in CTX. In total, 39 articles were reviewed, describing 55 CTX patients with a movement disorder. Additionally, we report on seven patients with parkinsonism out of our Dutch cohort of 79 (77 genetically proven) CTX patients. Mean age at onset of the movement disorder was 40 ± 12 years (median 40, range 13-62 years). Movement disorders can be considered a late disease manifestation. Parkinsonism was the most frequently reported movement disorder, followed by dystonia, myoclonus and postural tremor. Movement disorders were found to be mixed in 23% of patients and were usually part of a complex clinical picture, rather than a prominent symptom. Still, in 18% of the cases, a movement disorder was the presenting symptom. Unusual movement disorders represent a rare clinical feature in CTX, but CTX should be considered in the differential diagnosis of these movement disorders, particularly in case of early onset, and when associated with other neurological features (especially cognitive impairment, pyramidal and cerebellar signs) and/or with systemic features (such as diarrhoea, cataract and tendon xanthomas). CTX is a treatable disorder, stressing the importance of considering CTX as a potential cause of movement disorders.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cerebrotendinous xanthomatosis (CTX); Chenodeoxycholic acid; Movement disorders; Parkinsonism

Mesh:

Year:  2018        PMID: 30054180     DOI: 10.1016/j.parkreldis.2018.07.006

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  10 in total

1.  Parkinsonism with Normal Dopaminergic Presynaptic Terminals in Cerebrotendinous Xanthomatosis.

Authors:  Jun Li; Er-He Xu; Wei Mao; Hong-Wen Qiao; Yong-Tao Zhou; Qi Yang; Shu-Ying Liu; Piu Chan
Journal:  Mov Disord Clin Pract       Date:  2019-10-31

Review 2.  Skin Conditions and Movement Disorders: Hiding in Plain Sight.

Authors:  Kristina Kulcsarova; Janette Baloghova; Jan Necpal; Matej Skorvanek
Journal:  Mov Disord Clin Pract       Date:  2022-03-24

Review 3.  An Eye on Movement Disorders.

Authors:  Duncan Wilson; Mark Hallett; Tim Anderson
Journal:  Mov Disord Clin Pract       Date:  2021-08-10

Review 4.  Inherited metabolic diseases mimicking hereditary spastic paraplegia (HSP): a chance for treatment.

Authors:  Hélio A G Teive; Carlos Henrique F Camargo; Eduardo R Pereira; Léo Coutinho; Renato P Munhoz
Journal:  Neurogenetics       Date:  2022-04-09       Impact factor: 3.017

Review 5.  A Practical Approach to Early-Onset Parkinsonism.

Authors:  Giulietta M Riboldi; Emanuele Frattini; Edoardo Monfrini; Steven J Frucht; Alessio Di Fonzo
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.568

6.  c.1263+1G>A Is a Latent Hotspot for CYP27A1 Mutations in Chinese Patients With Cerebrotendinous Xanthomatosis.

Authors:  Jingwen Jiang; Guang Chen; Jingying Wu; Xinghua Luan; Haiyan Zhou; Xiaoli Liu; Zeyu Zhu; Xiaoxuan Song; Shige Wang; Xiaohang Qian; Juanjuan Du; Xiaojun Huang; Mei Zhang; Wei Xu; Li Cao
Journal:  Front Genet       Date:  2020-07-01       Impact factor: 4.599

7.  Gut Microbiota Dysbiosis Is Associated with Altered Bile Acid Metabolism in Infantile Cholestasis.

Authors:  Yizhong Wang; Xuefeng Gao; Xinyue Zhang; Yongmei Xiao; Jiandong Huang; Dongbao Yu; Xiaolu Li; Hui Hu; Ting Ge; Dan Li; Ting Zhang
Journal:  mSystems       Date:  2019-12-17       Impact factor: 6.496

Review 8.  A Proposed Diagnostic Algorithm for Inborn Errors of Metabolism Presenting With Movements Disorders.

Authors:  Juan Darío Ortigoza-Escobar
Journal:  Front Neurol       Date:  2020-11-13       Impact factor: 4.003

9.  Progressive Myoclonic Epilepsy'-like presentation of Cerebrotendinous Xanthomatosis in an Indian Family with A Novel C.646+1G>A Splice Site Mutation.

Authors:  Karan M Desai; Piyush Kumar; Parthvi S Ravat; Sangeeta H Ravat; Neeraj Jain; Shruti Agrawal; Rahil Ansari
Journal:  Epilepsy Behav Rep       Date:  2020-11-16

10.  Cerebrotendinous Xanthomatosis: Molecular Pathogenesis, Clinical Spectrum, Diagnosis, and Disease-Modifying Treatments.

Authors:  Shingo Koyama; Yoshiki Sekijima; Masatsune Ogura; Mika Hori; Kota Matsuki; Takashi Miida; Mariko Harada-Shiba
Journal:  J Atheroscler Thromb       Date:  2021-05-08       Impact factor: 4.928

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.